HOME >> MEDICINE >> NEWS
Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma

LOS ANGELES -- Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells. The complete findings are also available online in Blood.

"There were a number of fascinating findings," says Keith Bible, M.D., Ph.D., oncologist and the studys primary investigator. "In addition to observing many favorable aspects of chaetocin, we discovered some avenues for further research into other possible anti-myeloma agents."

Multiple myeloma is an incurable bone marrow cancer that kills more than 11,000 people each year in the United States, reports the American Cancer Society. Dr. Bibles team has shown for the first time that chaetocin has promising anti-myeloma activity. They found that chaetocins promise includes the ability to:

  • Kill myeloma cells harboring a diverse array of genetic abnormalities
  • Cause biological changes and induce oxidative stress in myeloma cells, leading to their death
  • Selectively kill myeloma cells with superior efficacy to commonly-used anti-myeloma drugs including dexamethasone and doxorubicin
  • Reduce myeloma growth in mice
  • Rapidly accumulate in cancer cells

The researchers were surprised that chaetocin, while structurally similar to anti-cancer agents known as histone deacetylase inhibitors (HDACIs), did not, at cytotoxic concentrations, seem to function as an HDACI; but instead that the cytotoxic mechanism appeared to be at least in part attributable to oxidative stress caused by chaetocin.

"Much more research needs to be done," says Jennifer Tibodeau, Mayo post-doctorate fellow and presenter of the study, "but we are hopeful that chaetocin may some day provide ne
'"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
15-Apr-2007


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... ... improve outcomes for patients with advanced heart failure, today announced that the company ... the amount of $555,358 from the National Heart, Lung, and Blood Institute of ...
(Date:8/28/2020)... ... August 28, 2020 , ... WHAT , Hespiro™ is ... with respiratory conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. ... exhaled gas and scrubs it free of carbon dioxide in a completely closed ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... Integrated ... Miami is the first Florida school to deploy its breakthrough Mobile Biodefense Indoor Air ... airborne COVID-19. True North Classical Academy plans to fully reopen equipped with the filtration ...
(Date:8/27/2020)... , ... August 27, 2020 , ... ... joined the Walk-in Dermatology team in its Greenvale, New York location. , ... and Skin Care Institute. She is certified in chemical peels, microdermabrasion, Hydrafacial MD, ...
(Date:8/26/2020)... , ... August 26, 2020 , ... ... speaker at the upcoming Global Inclusion Online Forum, leading a session entitled, “A ... first-ever online event of this magnitude designed to bring together the world’s leading ...
Breaking Medicine News(10 mins):
(Date:8/28/2020)... ... August 28, 2020 , ... Dr. Mark Surrey has been in ... serves as a clinical professor in the Department of OBGYN at UCLA’s David Geffen ... & Pacific Coast Reproductive Society and is a Clinical Director of Fellowship Training for ...
(Date:8/27/2020)... ... , ... Bleep LLC, maker of the DreamPort mask-less CPAP solution, announced today ... spokesperson. , “In my line of work, a good night of sleep is critical ... was a Bleeping no brainer for me,” said Jensen. “From the moment I started ...
(Date:8/26/2020)... ... August 26, 2020 , ... AseptiScope, a privately funded San Diego, California based, ... by MedTech Outlook. , “AseptiScope is pleased to receive this recognition,” said ... wear gloves on their hands, goggles on their eyes, covers on their shoes, and ...
Breaking Medicine Technology:
Cached News: